Cargando…

PB1892: IMATINIB RESISTANCE: THE ROLE OF PHARMACOGENETIC VARIABILITY IN A SOUTH AFRICAN COHORT

Detalles Bibliográficos
Autores principales:	De Long, C., February, F., Mashigo, N., Bassa, F., Swanepoel, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431590/ http://dx.doi.org/10.1097/01.HS9.0000850420.21495.b1

Ejemplares similares

PB1897: DISCONTINUATION OF IMATINIB IN PATIENTS FOLLOWED FOR CHRONIC MYELOID LEUKEMIA IN DEEP MOLECULAR RESPONSE
por: Bouchakor Moussa, Y., et al.
Publicado: (2022)

PB1956: EVALUATION OF AN INNOVATIVE NEW METHOD FOR QUANTITATION OF PLASMA CELLS ON CD138 IMMUNOHISTOCHEMISTRY
por: Gantana, E., et al.
Publicado: (2022)

PB1892: INCREASED INCIDENCE OF SRSF2 MUTATION WITH AGE INDICATING CLONAL HAEMATOPOIESIS IN PATIENTS WITH ACUTE MYELOID LEUKAEMIA: A SINGLE-CENTER EXPERIENCE
por: Richardson, Michelle, et al.
Publicado: (2023)

PB1898: BONE MARROW APLASIA – A RARE COMPLICATION OF IMATINIB THERAPY IN CML PATIENTS: ABOUT A CASE
por: chawad, W., et al.
Publicado: (2022)

PB1899: DEVELOPMENT AND VALIDATION OF A PREDICTIVE SCORING SYSTEM FOR THE PROGNOSIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE RECEIVING FIRST-LINE IMATINIB
por: Bektaş, M., et al.
Publicado: (2022)

PB1987: EVALUATION OF THE SECOND GENERATION TYROSINE KINASE INHIBITOR IN IMATINIB-RESISTANT OR -INTOLERANT CHRONIC PHASE, CHRONIC MYELOID LEUKEMIA ADULT PATIENTS
por: Bougherira, Soraya
Publicado: (2023)

PB1964: COMPARISON OF CLINICO-HEMATOLOGICAL PARAMETERS AND MOLECULAR AND CYTOGENETIC RESPONSE OF TWO BCR-ABL FUSION TRANSCRIPTS IN CHRONIC MYELOID LEUKEMIA TREATED WITH IMATINIB
por: Baraa, Laabidi, et al.
Publicado: (2023)

PB1762: PONATINIB VERSUS IMATINIB WITH REDUCED-INTENSITY CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME–POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): PHALLCON STUDY
por: Jabbour, E., et al.
Publicado: (2022)

PB1963: PSYCHIATRIC DISORDERS AS A FIRST MANIFESTATION OF SPORADIC CREUTZFELDT-JACOB DISEASE IN A PATIENT WITH CHRONIC MYELOID LEUKEMIA ON IMATINIB: UNUSUAL AND LIFE THREATENING ASSOCIATION
por: Smaili, Rachid, et al.
Publicado: (2023)

PB2045: POLYCYTHEMIA VERA IN YOUNG SUBJECTS: ABOUT A COHORT OF 11 CASES
por: Bougherira, S., et al.
Publicado: (2022)

PB1906: IS THERE A PLACE FOR IMATINIB IN THE FIRST-LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA CHRONIC PHASE: REAL LIFE DATA FROM UNIVERSITY CENTER AFTER LONG PERIOD OF FOLLOW-UP
por: Lekovic, D., et al.
Publicado: (2022)

PB1767: OUTCOME OF RELAPSED CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA IN THE SOUTH OF TUNISIA SINGLE CENTER EXPERIENCE
por: Siala, N., et al.
Publicado: (2022)

PB1836: ACUTE MYELOID LEUKEMIA IN OLDER ADULTS IN RESOURCE CONSTRAINT SETTING: SINGLE CENTER DATA FROM SOUTH INDIA
por: Paul, M., et al.
Publicado: (2022)

PB1867: PURINE ANALOGS ON HAIRY CELL LEUKAEMIA TREATMENT
por: Gomes, G., et al.
Publicado: (2022)

PB2052: CLINICOPATHOLOGIC VARIABLES AFFECTING DISEASE OUTCOME IN PRIMARY MYELOFIBROSIS. A SINGLE CENTER EXPERIENCE.
por: Elkourashy, S., et al.
Publicado: (2022)

PB1758: TWENTY-ONE YEARS’ EXPERIENCE OF THE EORTC 58951 PROTOCOL FOR THE TREATMENT OF CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA IN THE SOUTH OF TUNISIA
por: Frikha, I., et al.
Publicado: (2022)

PB1827: ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
por: Marques, I., et al.
Publicado: (2022)

PB2306: RELAPSE OF IMMUNE THROMBOCYTOPENIA AND MYOCARDITIS
por: Kapsouli, F., et al.
Publicado: (2022)

PB1732: CLINICAL CHARACTERISTICS AND THERAPEUTIC RESULTS OF CHILDHOOD AND YOUNG ADULTS T - ACUTE LYMPHOBLASTIC LEUKEMIA IN SOUTH OF TUNISIA
por: Frikha, Imen, et al.
Publicado: (2023)

PB2341: EARLY MORTALITY VARIABLES IN PATIENTS OLDER THAN 75 YEARS WITH DIFFUSE LARGE B-CELL LYMPHOMA
por: Pérez, Mónica Fernández, et al.
Publicado: (2023)

PB1942: HEPATIC MANIFESTATIONS OF CHILDHOOD HEMOPHAGOCYTIC LYMPHOHISTOCYTOSIS
por: El Sayed, M., et al.
Publicado: (2022)

PB1840: MONOCENTRIC EXPERIENCE OF VENETOCLAX-BASED REGIMENS FOR ACUTE MYELOID LEUKEMIA
por: Sciumè, M., et al.
Publicado: (2022)

PB2701: SAFETY OF 30 MINUTES INFUSION OF RITUXIMAB BIOSIMILAR. A COHORT STUDY.
por: Palomares, Laida Cuevas, et al.
Publicado: (2023)

PB1968: EPIGENETIC AND GENETIC INVESTIGATION OF SOCS-1 GENE IN PATIENTS WITH MULTIPLE MYELOMA
por: Serin, I., et al.
Publicado: (2022)

PB1876: SIXTEEN YEARS OF EXPERIENCE WITH THE MRC-10 PROTOCOL FOR THE TREATMENT OF ADULT ACUTE MYELOID LEUKEMIA IN THE SOUTH OF TUNISIA
por: Siala, Nour, et al.
Publicado: (2023)

PB2532: VARIABLE HEMATOLOGICAL AND CLINICAL PHENOTYPES IN DOUBLE HETEROZYGOTES OF ΒETA-THALASSEMIA AND TRIPLICATED ΑLPHA-GLOBIN GENES
por: Delaporta, Polyxeni, et al.
Publicado: (2023)

PB2288: THE ABO SYSTEM POLYMORPHISM IN ALGERIAN BLOOD DONORS
por: talbi, F., et al.
Publicado: (2022)

PB1981: EFFICACY AND SAFETY OF DENOSUMAB IN PATIENTS WITH MULTIPLE MYELOMA
por: Bougherira, S., et al.
Publicado: (2022)

PB2261: LINEZOLID AS A SAFE ANTIMICROBIAL AGENT IN THROMBOCYTOPENIC PATIENTS UNDERGOING CHEMOTHERAPY FOR HEMATOLOGIC MALIGNANCIES
por: Angotzi, F., et al.
Publicado: (2022)

PB1786: COMPARISON OF OPTICAL GENOME MAPPING WITH STANDARD OF CARE TESTING TO INVESTIGATE GENOMIC ABNORMALITIES IN LEUKAEMIAS: THE EXPERIENCE OF THE CENTRAL AND SOUTH GENOMIC LABORATORY HUB, UK
por: Muraru, M., et al.
Publicado: (2022)

PB1969: FUNCTIONAL CHARACTERIZATION OF SUSCEPTIBILITY LOCI TO MULTIPLE MYELOMA
por: Shokouhi, M., et al.
Publicado: (2022)

PB2034: TARGETED SEQUENCING LANDSCAPE OF A CHINESE PURE RED CELL ANEMIA COHORT
por: LI, Yue, et al.
Publicado: (2023)

PB2321: A COMPLEX GENOTYPE THAT TRANSLATES INTO A BLEEDING PHENOTYPE
por: Fonseca, L., et al.
Publicado: (2022)

PB1865: SINGLE-COUNTRY, MULTICENTER, RETROSPECTIVE, OBSERVATIONAL, DESCRIPTIVE COHORT STUDY OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH VENETOCLAX IN ARGENTINA (VENARG).
por: Pagano Vilar, C., et al.
Publicado: (2022)

PB2327: BONE MARROW STUDY IN THROMBOPENIA
por: López De Ugarriza, P., et al.
Publicado: (2022)

The pharmacogenetics of imatinib
por: Dulucq, Stéphanie, et al.
Publicado: (2010)

PB2074: IBRUTINIB AS A PROMISING TREATMENT FOR WALDENSTRÖM MACROGLOBULINEMIA
por: Ilhan, O., et al.
Publicado: (2022)

PB2200: CLONAL HEMATOPOIESIS AT THE CROSSROADS OF INFLAMMATORY BOWEL DISEASES AND HEMATOLOGICAL MALIGNANCIES: A BIOLOGICAL LINK?
por: Cumbo, C., et al.
Publicado: (2022)

PB2287: END OF LIFE TRANSFUSIONS IN PATIENTS WITH AN ONCOLOGICAL DIAGNOSIS
por: Duque, L., et al.
Publicado: (2022)

PB2044: TRIAL IN PROGRESS: OBSERVATIONAL STUDY IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED IN ITALY WITH MIDOSTAURIN (OVIDIO)
por: Grifoni, F. I., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jjb6998ldi6v32ha5fq02vlpf3